EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Senolytic drug reduces cancer resistance to PD-L1 blockade

Nourridine Siewe iD, Avner Friedman

PLOS One · 19.11.2026 · 21 (11) · e0362939

DOI: 10.1371/journal.pone.0362939 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, online erschienen am 19.11.2026. Verfasst von Nourridine Siewe und 1 weiteren Autor:innen. Beteiligte Einrichtung: School of Mathematics and Statistics, College of Science, Rochester Institute of Technology, Rochester, New York, United States of America. Hauptthemen laut MEDLINE: B7-H1 Antigen, Drug Resistance, Neoplasm, Senotherapeutics, Sulfonamides. Die Arbeit nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute of General Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Resistance to immune checkpoint inhibitors (ICIs), including anti-PD-L1 therapies, remains a major challenge in cancer treatment, with many patients relapsing despite initial responses. Here, we develop a mathematical model to investigate a mechanism of anti-PD-L1 resistance driven by age-associated senescence of CD8 + T cells, in which senescent T cells ( T s ) secrete VEGF, thereby promoting tumor growth through enhanced vascular support. To counteract this effect, we incorporate the senolytic drug navitoclax (ABT-263), which selectively eliminates senescent T cells, and evaluate the efficacy of combined senolytic–anti-PD-L1 therapy in extending tumor remission. Model predictions are validated against independent murine data involving navitoclax and anti-PD-L1 treatment. The model is used to study different strategies of combining the senolytic drug with anti-PD-L1, in order to maximize the remission time of the combined treatment. The optimal starting time of the treatment with the senolytic drug depends on the senescent-to-functional T cells ratio, T s / T . The paper identifies immune senescence as an important determinant of response to cancer immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

B7-H1 AntigenDrug Resistance, NeoplasmSenotherapeuticsSulfonamidesImmune Checkpoint InhibitorsAniline CompoundsNeoplasmsAnimalsHumansMiceCD8-Positive T-LymphocytesT-Cell Senescence

Substanzen

B7-H1 AntigennavitoclaxSenotherapeuticsSulfonamidesImmune Checkpoint InhibitorsAniline CompoundsCD274 protein, human

Autor:innen und Institutionen

  • School of Mathematics and Statistics, College of Science, Rochester Institute of Technology, Rochester, New York, United States of America.
  • Department of Mathematics, The Ohio State University, Columbus, Ohio, United States of America.

ORCID-Profile: Nourridine Siewe

Förderung

  • National Institute of General Medical Sciences

Zitieren

APA

Siewe, N., & Friedman, A. (2026). Senolytic drug reduces cancer resistance to PD-L1 blockade. PLOS One, 21(11), e0362939. https://doi.org/10.1371/journal.pone.0362939

Vancouver

Siewe N, Friedman A. Senolytic drug reduces cancer resistance to PD-L1 blockade. PLOS One. 2026;21(11):e0362939. doi:10.1371/journal.pone.0362939

BibTeX
@article{Siewe2026,
  author = {Siewe, Nourridine and Friedman, Avner},
  title = {Senolytic drug reduces cancer resistance to PD-L1 blockade},
  journal = {PLOS One},
  year = {2026},
  volume = {21},
  number = {11},
  pages = {e0362939},
  doi = {10.1371/journal.pone.0362939}
}
Kostenlos starten →